Immunologic Factor – Page 8

RFK Jr. claims placebo-controlled vaccine trials are’radical departure’ from past. Experts disagree

3 months ago talkbio0Tagged Approved, CHARGE Syndrome, Effectiveness, experts, HHS, placebo-controlled trials, Policy, RFK Jr., Vaccines

Vaccines, placebo-controlled trials, CHARGE Syndrome, experts, Effectiveness, RFK Jr., Policy, Approved, HHS

Trumps US Manufacturing Push, New Vaccine Policy, Novos Weight Loss Pill up for FDA Review

3 months ago talkbio0Tagged Policy, trade deficits, United States Food and Drug Administration, Vaccines

Policy, trade deficits, Vaccines, United States Food and Drug Administration

Generation Gold Standard: HHS’s $500 Million Initiative for Universal Vaccine Development

3 months ago talkbio0Tagged Bhattacharya, BPL, Genus: Coronavirus, Jay, NIH Mouse, pandemic preparedness, propiolactone, Universal, Vaccines, whole-virus

Universal vaccines, beta-propiolactone (BPL), whole-virus platform, influenza, coronavirus, NIH, Jay Bhattacharya, Robert F. Kennedy Jr., pandemic preparedness

HHS to require all “new vaccines” to be tested against placebo

3 months ago talkbio0Tagged COVID19 (disease), HHS, placebo-controlled trials, Placebos, Policy, Testing, Vaccines

Vaccines, HHS, placebo-controlled trials, COVID19 (disease), Testing, Placebos, Policy

FDA Approves Johnson & Johnson’s Imaavy: A New Treatment Option for Generalized Myasthenia Gravis

3 months ago talkbio0Tagged Approved, Autoimmune Diseases, Blocker, FCGRT gene, FcRn, Imaavy, immunoglobulin G, Myasthenia Gravis, Generalized, nipocalimab-aahu, United States Food and Drug Administration

Imaavy, nipocalimab-aahu, FcRn blocker, generalized myasthenia gravis (gMG), FDA approval, Johnson & Johnson, autoimmune disease, IgG reduction

Regeneron crumples under the weight of missed Eylea expectations

3 months ago talkbio0Tagged decline, earnings, Eylea, Regeneron, Sales - occupational activity, United States Food and Drug Administration

Regeneron, United States Food and Drug Administration, earnings, Eylea, decline, Sales – occupational activity

HHS lifts stop work order on Vaxart’s COVID-19 trial, continues funding for the 10,000-participant study

3 months ago talkbio0Tagged BARDA, Covid Vaccine, COVID19 (disease), Lifting, next-generation, oral pill vaccine, Phase 2b Trial, stop work, Vaccines, Vaxart

Vaxart, COVID-19 vaccine, oral pill vaccine, stop work order lifted, BARDA funding, 10, 000-participant study, Phase 2b trial, next-generation COVID vaccine

France pauses chikungunya vaccinations in the elderly after patient death

3 months ago talkbio0Tagged Adverse event, Age, Chikungunya Fever, Disease Outbreaks, Elderly (population group), France, Latex Fixation Tests, older, Reunion Island, Vaccination, Vaccines

Vaccines, Chikungunya Fever, Elderly (population group), Adverse event, France, Latex Fixation Tests, Reunion Island, Disease Outbreaks, Age, older, Vaccination

‘Deviated from the core’: Akeso CEO tries to reset expectations of bispecific’s survival readout amid market tumult

3 months ago talkbio0Tagged Antibodies, Bispecific, Ivonescimab, Keytruda, Keytruda head-to-head trial, Market, Non-Small Cell Lung Carcinoma, Overall Survival, PD-1xVEGF, Reaction, summit

Ivonescimab, PD-1xVEGF bispecific antibody, Overall survival (OS) readout, Keytruda head-to-head trial, HARMONi-2 trial, Non-small cell lung cancer (NSCLC), Market reaction, Summit Therapeutics

Regeneron Secures EU Approval for Bispecific Antibody Lynozyfic, Positioning for Competition Against J&J and Pfizer

3 months ago talkbio0Tagged Antibodies, Bispecific, Approved, EU, J&J, Lynozyfic, Multiple Myeloma, Neoplasms, Pfizer, Regeneron

Regeneron, Lynozyfic, Bispecific Antibody, Multiple Myeloma, EU Approval, J&J, Pfizer, Oncology